EB
The startup develops multifunctional therapeutics that activate the immune response to enhance antitumor activity and target resistance mechanisms specific to individual tumor microenvironments. This approach aims to improve treatment outcomes for patients with difficult-to-treat and resistant cancers.
Updated 3 months ago
Funding
$40M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops multifunctional therapeutics that activate the immune response to enhance antitumor activity and target resistance mechanisms specific to individual tumor microenvironments. This approach aims to improve treatment outcomes for patients with difficult-to-treat and resistant cancers.